TradeFlare's AI research teams analysed SVRA on 5 market nights between July 14, 2026 and July 21, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 21, 2026 | BUY | $5.49 | — / — | -8.7% | -8.1% | The current setup does not warrant a trade. |
| July 20, 2026 | BUY | $5.52 | — / — | -1.1% | -2.2% | Pending FDA decision on critical drug development programs. |
| July 17, 2026 | BUY | $5.52 | — / — | -0.2% | -2.5% | Potential FDA approval for Molbreevi. |
| July 15, 2026 | BUY | $5.69 | — / — | -2.8% | -1.9% | The current setup does not meet the minimum requirements for a trade. |
| July 14, 2026 | BUY | $5.74 | — / — | +2.6% | -2.1% | Positive clinical trial developments for MOLBREEVI. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.